DBV Technologies
Update in progressDBVT (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
DBV Technologies S.A. is a clinical‑stage biopharma focused on epicutaneous immunotherapy. Its lead product Viaskin Peanut has completed Phase 3 for peanut allergy, while Viaskin Milk is in Phase 1/2 for IgE-mediated or cow’s milk allergy and eosinophilic esophagitis. Early programs include RSV vaccine, IBD, celiac disease, and type I diabetes. The Viaskin platform underpins these efforts, with a Nestlé Health Science collaboration on MAG1C for non‑IgE CMPA. Founded 2002, based in Châtillon, France.
Company score
- Sentiment
- 0.37
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.38
- Governance
- 0.07
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.13
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.25
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!